Directory
Xavier Matias-Guiu Guia

Xavier Matias-Guiu Guia

Degree: PhD

973 705 340
fjmatiasguiu.lleida.ics(ELIMINAR)@gencat.cat

ResearcherID: http://www.researcherid.com/rid/C-3039-2009

Publications

  • MATIASGUIU, X; LaGuette, J; PurasGil, AM; Rosai, J

    Metastatic neuroendocrine tumors to the thyroid gland mimicking medullary carcinoma: a pathologic and immunohistochemical study of six cases

    AMERICAN JOURNAL OF SURGICAL PATHOLOGY 21 754-762. .

    [doi:10.1097/00000478-199707000-00003]

  • Berna, LI; Flotats, A; PuigDomingo, M; Piera, J; MATIASGUIU, X; Caixas, A; Estorch, M; Catafau, A; Mari, C; Carrio, I

    Tc-99m-MIBI in the localization of parathyroid abnormal glands in patients presenting with primary hyperparathyroidism.

    Journal Of Nuclear Medicine 38 609-609. .

  • Berna, LI; Mari, C; Chico, A; Piera, J; MATIASGUIU, X; Alonso, C; Flotats, A; Estorch, M; Catafau, A; Carrio, I

    In-111-octreotide in the localization of recurrent medullary thyroid carcinoma.

    Journal Of Nuclear Medicine 38 613-613. .

  • Cuatrecasas, M; Villanueva, A; MATIASGUIU, X; Prat, J

    K-ras mutations in mucinous ovarian tumors - a clinicopathologic and molecular study of 95 cases

    CANCER 79 1581-1586. .

    [doi:10.1002/(SICI)1097-0142(19970415)79:8<1581::AID-CNCR21>3.0.CO;2-T]

  • Garcia, A; MATIASGUIU, X; Cabezas, R; Chico, A; Prat, J; Baiget, M; DeLeiva, A

    Molecular diagnosis of von Hippel-Lindau disease in a kindred with a predominance of familial phaeochromocytoma

    CLINICAL ENDOCRINOLOGY 46 359-363. .

    [doi:10.1046/j.1365-2265.1997.00149.x]

  • MATIASGUIU, X; Pons, C; Prat, J

    Alpha-inhibin, mullerian inhibiting substance and CD 99 expression in functioning ovarian tumors.

    LABORATORY INVESTIGATION 76 607-607. .

  • MATIASGUIU, X; Garcia, A; Cabezas, R; Chico, A; Baiget, M; DeLeiva, A; Prat, J

    Molecular diagnosis of VonHippel-Lindau disease in familial pheochromocytoma

    LABORATORY INVESTIGATION 76 280-280. .

  • MATIASGUIU, X; Lagarda, E; Calaf, M; Azpiroz, A; DeLeiva, A; Prat, J; Baiget, M

    Identification of a novel somatic mutation in the RET proto oncogene in a patient with sporadic medullary thyroid carcinoma

    HUM MUTAT 9 476-476. .

    [doi:10.1002/(SICI)1098-1004(1997)9:5<476::AID-HUMU20>3.0.CO;2-Z]

  • MATIASGUIU, X; Villanueva, A; Cuatrecasas, M; Capella, G; DeLeiva, A; Prat, J

    p53 in a thyroid follicular carcinoma with foci of poorly differentiated and anaplastic carcinoma

    PATHOL RES PRACT 192 1242-1249. .

  • Fornas, O; Mato, ME; Viader, M; Oliver, B; Tresserres, P; Bartumeus, F; Tugues, D; Petriz, J; MATIASGUIU, X; Webb, SM

    Flow cytometry analysis of pituitary adenomas

    Hormone Research 46 257-262. .

    [doi:10.1159/000185097]

  • Biarnes, J; Miranda, M; Corral, J; Gabau, E; MATIASGUIU, X; Matilla, A; Soler, J; Estivill, X; Volpini, V

    The molecular pathology of RET protooncogen in families with multiple endocrine neoplasm type 2a

    MEDICINA CLINICA 107 321-325. .

  • Domingo, P; Rodriguez, P; LopezContreras, J; Rebasa, P; Mota, S; MATIASGUIU, X

    Spontaneous rupture of the spleen associated with pneumonia

    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES 15 733-736. .

    [doi:10.1007/BF01691960]

Projects

  • Homologous recombination deficiency in high-grade endometrial cancers. Biomarkers and impact of intratumor heterogeneity.
  • EPH Receptor Signaling in Endometrial Cancer
  • Ajuts per a la contractació de personal investigador novell (FI)
  • Personalized Immunotherapy for Endometrial Cancer; Acronym: ExCITE (Endometrial Cancer Immunotherapy)
  • "Multi-Omics data for Cancer Research and the Development of New Diagnostics and Therapies"
  • EFFICACY: Nuevas estrategias para incrementar efectividad de los tratamientos con ABTL0812
  • Incorporación de nuevas areas temáticas y nuevos grupos al consorcio CIBER
  • Perfiles epigenéticos asociados a patrones de metastasis en cáncer de endometrio
  • CONTRACTES D'INCORPORACIO DE CIENTIFICS I TECNOLEGS: INCORPORACIO D'UNA DOCTORA PER A L'ACCIO ANTITUMORAL DELS CANNABINOIDES EN EL CARCINOMA D'ENDOMETRI
  • DISCOVERY, VALIDATION AND IMPLEMENTATION OF BIOMARKERS FOR PRECISION ONCOLOGY
  • Desarrollo de nuevas aproximaciones en el manejo individualizado de pacientes con cancer ginecológico (PREDICTGYN)
  • VALIDACION DE ANEXINA 2 COMO PREDICTOR DE RECIDIVA EN EL CANCER DE ENDOMETRIO. DISEÑO DE NUEVAS ESTRATEGIAS TERAPEUTICAS. ANXARECU